"Skin cancer cure hope for millions as major treatment breakthrough sees man's tumors disappear 'completely'."
The study was carried out by researchers from the Fred Hutchinson
Cancer Research Center, the University of Washington, and the Memorial
Sloan-Kettering Cancer Center, all in the US.
Funding was provided by the Cancer Research Institute and a "Stand Up
To Cancer" Cancer Research Institute Cancer Immunology Dream Team
Translational Research Grant.
The researchers aimed to transfuse melanoma-specific CTLs that were
first "primed" by a signalling protein called interleukin-21 (IL-21),
which would help boost the numbers of these T cells.
These enhanced CTLs were combined with anti-CTLA4 to see if this would help the skin cancer patient. "Combining CTLA4 blockade with the transfer of well-characterized,
robust antitumor CTLs represents an encouraging strategy to enhance the
activity of the adoptively transferred CTL and induce de novo antitumor
responses.
"This strategy may hold broad promise for immune checkpoint blockade-resistant melanomas."
These seem to be extremely encouraging findings for metastatic melanoma, a cancer with notoriously poor prognosis.
However,it must be emphasized that this case report focuses on just one man.
No comments:
Post a Comment